0HV Stock Chart & Stats
€22.00
-€0.40(-1.79%)
At close: 4:00 PM EDT
€22.00
-€0.40(-1.79%)
Day’s Range― - ―
52-Week Range€16.20 - €25.80
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€3.97B
Enterprise Value€5.00K
Total Cash (Recent Filing)€1.13K
Total Debt (Recent Filing)€1.59K
Price to Earnings (P/E)48.7
Beta0.74
Next Earnings
Nov 04, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding160,617,700
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)1.17
Price to Sales (P/S)1.34
P/FCF Ratio15.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.31Price Target Upside19.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)1.32
Revenue Forecast (FY)€2.50B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationConsistent and rising free cash flow (TTM ~$232M and Q2 $105M) with management targeting ~100% conversion indicates durable cash conversion. That strengthens funding for R&D, buybacks and M&A, reduces refinancing risk, and supports reinvestment without relying on volatile earnings.
High And Expanding Gross And EBITDA MarginsStable mid-50% gross margins and recent EBITDA expansion reflect strong product economics and price/mix resilience. Durable gross margins support long-term profitability even if sales mix shifts, while operating leverage converting revenue growth into higher EBITDA margins improves structural earnings quality.
Moderate Leverage And Financial FlexibilityLow-to-moderate leverage (net debt/EBITDA ~0.7x, D/E ~0.5) provides balance-sheet flexibility to pursue strategic M&A, repurchase shares, and invest commercially. This financial headroom reduces vulnerability to shocks and supports multi-period strategic initiatives without straining liquidity.
Bears Say
Thin And Volatile Net ProfitabilityNet margin near 3% and a history of swings (losses in 2023–24) means small revenue or cost shocks can push results negative. Persistent thin bottom-line profitability limits internal reinvestment, stresses returns on equity, and raises forecasting risk over the next several quarters.
Regulatory Pricing Risk In China (VBP)Procurement reforms in China (VBP) represent a structural headwind for implant pricing, a high-value segment. Expected 10%–15% price declines could materially reduce regional revenue and margins, and the uncertain timing complicates medium-term planning for pricing, mix, and investment cadence.
Exposure To Cyclical Elective CategoriesA meaningful portion of sales comes from elective dental procedures and capital equipment, which are sensitive to macro and regional trends. This structural exposure can produce uneven demand, amplifying revenue and margin cyclicality and complicating steady multi-quarter growth and resource planning.
0HV FAQ
What was Envista Holdings Corp’s price range in the past 12 months?
Envista Holdings Corp lowest stock price was €16.20 and its highest was €25.80 in the past 12 months.
What is Envista Holdings Corp’s market cap?
Envista Holdings Corp’s market cap is €3.97B.
When is Envista Holdings Corp’s upcoming earnings report date?
Envista Holdings Corp’s upcoming earnings report date is Nov 04, 2026 which is in 83 days.
How were Envista Holdings Corp’s earnings last quarter?
Envista Holdings Corp released its earnings results on Aug 05, 2026. The company reported €0.356 earnings per share for the quarter, beating the consensus estimate of €0.291 by €0.065.
Is Envista Holdings Corp overvalued?
According to Wall Street analysts Envista Holdings Corp’s price is currently Undervalued.
Does Envista Holdings Corp pay dividends?
Envista Holdings Corp does not currently pay dividends.
What is Envista Holdings Corp’s EPS estimate?
Envista Holdings Corp’s EPS estimate is 0.31.
How many shares outstanding does Envista Holdings Corp have?
Envista Holdings Corp has 160,617,700 shares outstanding.
What happened to Envista Holdings Corp’s price movement after its last earnings report?
Envista Holdings Corp reported an EPS of €0.356 in its last earnings report, beating expectations of €0.291. Following the earnings report the stock price went up 4.386%.
Which hedge fund is a major shareholder of Envista Holdings Corp?
Currently, no hedge funds are holding shares in DE:0HV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envista Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€26.31 (19.59% Upside)
€26.31 (19.59% Upside)
Blogger Sentiment
Bullish
DE:0HV Sentiment 83%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.19%
Trailing 12-Months
Company Description
Envista Holdings Corp
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
0HV Company Deck
0HV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported a strong quarter with broad-based revenue growth, meaningful margin expansion, large EPS and free-cash-flow improvement, a strengthened balance sheet and raised full-year guidance. Operational highlights included robust E&C performance, double-digit Spark growth, successful new product launches, and continued share gains. Headwinds and risks were manageable and largely named and quantified: China VBP-driven price pressure and timing uncertainty, a Q4 billing-day calendar headwind, tariff-related costs, and the end of a small deferral tailwind. Overall, management framed the issues as addressable while emphasizing continued momentum, investment in R&D and commercial initiatives, and confidence in the raised guidance.View all DE:0HV earnings summaries0HV Revenue Breakdown
63.99% Specialty Products & Technologies
36.01% Equipment & Consumables

0HV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€26.31
▲(19.59% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
DENTSPLY SIRONA
―
Disc Medicine
―
Clover Health Investments
―
AbCellera Biologics
―
Bausch + Lomb Corporation
―









